Tafamidis emerges as first specific treatment for ATTR-CM
Treatment with tafamidis led to a reduction in all-cause mortality and cardiovascular (CV)-related hospitalizations among patients with transthyretin amyloid cardiomyopathy (ATTR-CM), according to the phase III ATTR-ACT* trial.

New Molecule

2 New

New Formulation

1 New

New Brand

1 New

Color 1
Color 2
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in